Medivation Is for Sale: How Much Should It Get?
Considering the prospects for the pipeline, Medivation should get more than what Sanofi offered. It will probably get more than what Pharmacyclics received.
How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.
Pfizer’s Medivation Acquisition: What You Need to Know
On August 22, Medivation (MDVN) and Pfizer (PFE) entered into a definitive agreement. Pfizer will acquire Medivation for a consideration of ~$14 billion.
A Look at Mallinckrodt’s Operating Segments
Mallinckrodt (MNK) is a specialty pharmaceuticals company that relies on volume-driven growth. Let’s discuss the performances of its three segments.
A Look at the Pfizer-Medivation Deal
Pfizer-Medivation deal On September 27, 2016, Pfizer (PFE) completed the acquisition of Medivation (MDVN). The stock transaction is valued at $81.50 per Medivation share, resulting in a total enterprise value of ~$14 billion. What is Medivation? Medivation is a California-based biopharmaceutical company. It is focused on developing and commercializing innovative therapies for the treatment of […]
Higher Discontinuations Are among Orkambi’s Concerns
Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.
How Ionis Pharmaceuticals’ Valuation Compares to Its Peers
Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.
Can Mallinckrodt Expand Its Margins?
Wall Street analysts expect Mallinckrodt’s (MNK) net margin to jump to 24.3% in 3Q16 from 10% in 3Q15.
Regeneron’s Dupilumab: How Much Potential Does It Hold?
Dupilumab has a breakthrough therapy designation from the FDA for the indication of moderate-to-severe atopic dermatitis in adults.
Could Medivation’s Xtandi Become a Major Urology Drug?
Although Medivation’s (MDVN) Xtandi is a leader in the oncology space, it has significant opportunity in the urology space as well.
Opportunities For Xtandi, Medivation’s Key Drug
Enzalutamide, known by its brand name Xtandi, is an androgen receptor inhibitor. It is the only commercialized product in Medivation’s (MDVN) portfolio.
Ionis Pharmaceuticals: Valuation Compared to Its Peers
In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.
Medivation and Bluebird Led IBB’s Mid-Cap Stocks Last Week
Medivation and Bluebird led IBB’s mid-cap stocks for the week ended September 18, 2015.